Compare Cardinal Health Inc (CAH) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cardinal Health Inc vs Recursion Pharmaceuticals Inc — how do they compare? Cardinal Health Inc trades at $240.52 (market cap $55.88B), while Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.81B). The key difference: Cardinal Health Inc is far larger — about 30.9× Recursion Pharmaceuticals Inc's market cap, and Cardinal Health Inc pays a 0.86% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CAH | RXRX | |
|---|---|---|
Market Cap | $55.88B | $1.81B |
Sector | Health | Health |
52-Week High | $240.26 | $6.79 |
52-Week Low | $146.04 | $2.84 |
Enterprise Value | $59.91B | $1.33B |
Dividend Yield | 0.86% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cardinal Health Inc
Cardinal Health is a leading pharmaceutical wholesaler, engaged in the sourcing and distribution of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail-order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and McKesson, the three compose well over 90% of the U.S. pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Read more on CAH →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
